Tityus serrulatus envenoming in non-obese diabetic mice: a risk factor for severity

Abstract

Background  In Brazil, accidents with venomous animals are considered a public health problem. Tityus serrulatus (Ts), popularly known as the yellow scorpion, is most frequently responsible for the severe accidents in the country. Ts envenoming can cause several signs and symptoms classified according to their clinical manifestations as mild, moderate or severe. Furthermore, the victims usually present biochemical alterations, including hyperglycemia. Nevertheless, Ts envenoming and its induced hyperglycemia were never studied or documented in a patient with diabetes mellitus (DM). Therefore, this is the first study to evaluate the glycemia during Ts envenoming using a diabetic animal model (NOD, non-obese diabetic).

Methods  Female mice (BALB/c or NOD) were challenged with a non-lethal dose of Ts venom. Blood glucose level was measured (tail blood using a glucose meter) over a 24-h period. The total glycosylated hemoglobin (HbA1c) levels were measured 30 days after Ts venom injection. Moreover, the insulin levels were analyzed at the glycemia peak.

Results  The results demonstrated that the envenomed NOD animals presented a significant increase of glycemia, glycosylated hemoglobin (HbA1c) and insulin levels compared to the envenomed BALB/c control group, corroborating that DM victims present great risk of developing severe envenoming. Moreover, the envenomed NOD animals presented highest risk of death and sequelae.

Conclusions  This study demonstrated that the diabetic victims stung by Ts scorpion should be always considered a risk group for scorpion envenoming severity.

Tityus serrulatus; Diabetes mellitus; Scorpion venom; NOD mice; Glycemia

Background

In Brazil, accidents involving venomous animals are considered a public health problem. Tityus serrulatus(Ts), popularly known as the yellow scorpion, is most frequently responsible for these accidents. During the period from 2000 to 2015, 727,113 cases of scorpion envenoming were reported in Brazil, with 1026 deaths and a mortality rate of 0.14 % [¹, ², ³, ⁴].

Envenoming by Ts can cause several signs and symptoms according to not only the content of venom, but also the victim’s body weight, the blood-brain-barrier permeability, sex, health conditions and sting location. The mild envenoming is characterized by an intense local pain and possible paresthesia. Moderate envenoming manifests through local pain as well as nausea, sweating, vomiting, tachycardia, tachypnea and increasing of blood pressure. Severe envenoming presents the same symptoms of moderate followed by agitation and exhaustion, abdominal pain, stiffness and muscle spasms, convulsions, fever, dehydration, cardiac arrhythmias, heart failure and even coma [⁵, ⁶, ⁷, ⁸, ⁹, ¹⁰, ¹¹]. Moreover, biochemical alterations are also observed during Ts envenoming such as hyperglycemia [⁶, ¹², ¹³, ¹⁴, ¹⁵].

Hyperglycemia is a sign constantly observed in diabetic individuals. Diabetes mellitus (DM) currently affects about 314 million people worldwide. Solely in 2012, it was responsible for 1.5 million deaths according to the World Health Organization (WHO). Currently, based on the etiology of the disease, DM can be classified into two types: type 1 and type 2 [¹⁶]. Although the pathologies have different origins, both have similar signs and symptoms such as hyperglycemia, polyuria, polyphagia, polydipsia, unexplained weight loss and may also include foot pain, blurred vision, frequent infections and even coma [¹⁷, ¹⁸].

The type 1 DM, or insulin-dependent DM, has a genetic etiology with the most common type being among children and juveniles. It is an autoimmune disease in which self-reactive T cells induce the B cell production of specific antibodies against beta cells of the islets of Langerhans. This autoimmune mechanism results in the destruction of these cells and consequently the decrease of insulin production [¹⁹, ²⁰]. On the other hand, type 2 DM is the most common type of diabetes (accounts for 90 %). It is considered a chronic metabolic disorder and has been characterized by impaired insulin action and/or abnormal insulin secretion and eventual pancreatic beta-cell failure. An early abnormality in the disease is insulin resistance, which is the key linking factor for the metabolic syndrome disease cluster of glucose intolerance, hypertension and dyslipidemia [²¹, ²², ²³].

The model employing non-obese diabetic (NOD) animals is useful for type 1 diabetes, and presents an autoimmune genetic disease where T cells (CD4⁺andCD8⁺) become self-reactive to pancreatic islets, resulting in inflammation during the first 3 to 4 weeks of life. However, only after mice reach 4 to 6 months of age does it become possible to verify insulitis, which results in insulin deficiency and therefore the clinical signs of diabetes [²⁴, ²⁵]. Thus, based on the Ts venom-induced hyperglycemia and the high incidence of diabetic patients, this is the first study to investigate the Ts envenoming complications in DM individuals, using NOD mice as the experimental model.

Methods

T. serrulatus venom

The Ts scorpions, collected from the Ribeirão Preto region, were kept in the Serpentarium of the Medical School of RibeirãoPreto (FMRP/USP). The venom extraction from 145 scorpions was performed using the telson electrical stimulation method ─ 12 mV [²⁶]. After extraction, the pooled venom was desiccated and stored at –20 °C. The use of Ts venom was approved by the Genetic Patrimony Management Board (CGEN/MMA), through the Access and Shipment Component of Genetic Heritage for scientific research purposes (number 010174/2014-1).

Mass assessment of the venom of T. serrulatus

The desiccated venom was dispersed in 1 mL of ultrapure water and centrifuged at 10,015 ×g, 4 °C for 10 min, and the supernatant was stored at 4 °C. The pellet was resuspended using the same conditions. The total supernatant (2 mL) resulted in soluble pooled venom without the presence of mucus.

The mass of soluble pooled venom was estimated by absorbance readings at 280 nm using the NanoDrop spectrophotometer 2000 (Thermo Scientific, USA) and the extinction coefficient of the soluble venom [²⁷]:

Tricine-SDS-PAGE

The venom was analyzed using tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (Tricine-SDS-PAGE) according to the method used for ultra-low-mass proteins [²⁸]. The 16.5 % separating gel used was overlaid by a 5 % stacking gel. Samples consist of different masses of Ts venom (10, 20 and 30 μg) and the molecular mass marker (M-3546, Sigma-Aldrich®, USA). The gel was stained with Coomassie Blue plus one PhastGel® R-350 (GE Healthcare, Sweden) and destained with 10 % acetic acid (V/V).

Animals

Females of BALB/c and NOD lineage (18–25 g) were obtained from the biotherium of the School of Pharmaceutical Sciences of Ribeirão Preto (FCFRP/USP) and the biotherium of the Ribeirão Preto Medical School (FMRP/USP), respectively. The animals were kept in cages with filters in an air-conditioned environment (23 ± 1 °C, 55 ± 5 % humidity) until the blood glucose values of NOD animals became significantly higher than those of the controls (BALB/c), indicating the hyperglycemia characteristic of the diabetic state (15 weeks old). Food and water were provided ad libitum. Mouse experimental models are in accordance with the Ethical Principles in Animal Experimentation under the license number 13.1.372.53.0.

Basal blood glucose levels and T. serrulatus venom dose

The basal glucose levels of BALB/c and NOD mice were measured in tail blood using a glucose meter (One Touch Ultra®, Lifescan, USA). The dose of Ts venom capable of inducing hyperglycemia in mice (BALB/c and NOD) was also adjusted. The doses of 1 mg/kg and 0.5 mg/kg were tested in the different mouse species.

Kinetic assay of glucose induced by T. serrulatus venom

Groups of female BALB/c or NOD mice (18–25 g, n= 4) were challenged with a non-lethal dose of Ts venom (0.5 mg/kg) using subcutaneous injection (similar to scorpion sting site), diluted in sterile physiological solution (0.9 % W/V of NaCl) in a final volume of 0.2 mL. Control groups received only sterile physiological solution. Glucose was measured in tail blood using a glucose meter (One Touch Ultra®, Lifescan, USA). Blood glucose was measured over a 24-h period (at 0, 1, 2, 3, 4, 5, 6, 12 and 24 h).

Glycosylated hemoglobin (HbA1c) induced by T. serrulatus venom

Groups of female BALB/c or NOD mice (18–25 g, n= 4) were challenged with a non-lethal dose of Ts venom (0.5 mg/kg) using subcutaneous injection (similar to scorpion sting site), diluted in sterile physiological solution (0.9 % W/V of NaCl) in a final volume of 0.2 mL. Control groups received only sterile physiological solution. After 30 days (to reflect mean glycemia for the previous 30 days), 0.5 mL of blood from the retro-orbital cavity was collected in heparinized tubes under intraperitoneal anesthesia: ketamine 60 mg/kg (Dopalen, Agripands Brasil Ltda®, Brazil) and xylazine 8 mg kg (Rompun, Bayer Animal Health®, Brazil). The blood was centrifuged at 10,000 rpm for ten minutes, at 4 °C, to obtain the plasma. The measurement of total glycosylated hemoglobin (HbA1c) levels was performed according to the manufacturer’s instructions (Doles®, Brazil).

Insulin levels induced by T. serrulatus venom

Groups of female BALB/c or NOD mice (18–25 g, n= 4) were challenged with a non-lethal dose of Ts venom (0.5 mg/kg) using subcutaneous injection (similar to scorpion sting site), diluted in sterile physiological solution (0.9 % W/V of NaCl) in a final volume of 0.2 mL. Control groups received only sterile physiological solution. After reaching the hyperglycemia peak (1 h after envenomation), 0.5 mL of blood from the retro-orbital cavity was collected in heparinized tubes under anesthesia. The blood was centrifuged at 10,000 rpm for 10 min, at 4 °C, to obtain the plasma. The insulin assay was performed using the immunoassay method according to the manufacturer’s instructions (Ultra Sensitive Mouse Insulin ELISA kit, Crystal Chem, USA).

Results

T. serrulatus venom mass and electrophoresis

The pooled venom obtained from 145 Ts scorpions resulted in 21 mg of soluble venom, a median of 0.14 mg per scorpion.

The Tricine-SDS-PAGE indicates the Ts venom protein profile using different masses (10, 20 and 30 μg) (Fig. 1). Two main bands of low molecular masses were observed. The sodium-channel toxins (NaTxs; from 60 to 76 amino acid residues) are the main proteins evidenced in the electrophoretic band of molecular mass between 6000 and 8000 Da, whereas the potassium-channel toxins (KTxs; from 22 to 47 amino acid residues) are the main components of the electrophoretic band from 5000 to 4000 Da.

Fig. 1
Electrophoretic profile of the pooled Ts venom. Molecular mass markers (lane 1); pooled Ts venom: 10, 20 and 30 μg (lanes 2, 3 and 4, respectively). NaTxs: voltage-gated sodium channel toxins. KTxs: voltage-gated potassium channel toxins. Coomassie Blue plus one PhastGel® R-350 staining

T. serrulatus venom increased the glucose levels of mice

The median basal glucose – time 0, before Ts venom (TsV) injection – was 82.9 and 125 mg/dL for BALB/c and NOD mice, respectively (Fig. 2a). Ideally, NOD mice are considered diabetic with glucose levels higher than 200 mg/dL. However, during the experimental design standardization using NOD mice, we observed that both the dose of Ts venom and the glucose basal levels were limiting factors to the experiment, inducing lethality of 25 to 100 % (Fig. 2b). Therefore, we decided to use NOD animals presenting glucose levels lower than 150 mg/dL, but significantly higher than glucose levels of the BALB/c control (p< 0.001) and the Ts venom concentration of 0.5 mg/kg (100 % survival).

Fig. 2
Standardization of basal glucose levels and T. serrulatus venom dose. a Basal glucose (time 0, before TsV injection) was measured in tail blood extracted from mice using a glucose meter (One Touch Ultra®, Lifescan, USA). Results are expressed as means ± SD (n= 4), which were analyzed by paired t test (*p< 0.001). b NOD survival using different glucose basal levels (> 200, < 200 and < 150 mg/dL) and T. serrulatus venom (TsV) concentrations (0.5 and 1 mg/kg)

All mouse groups that received 0.5 mg/kg of Ts venom showed hyperglycemia 1 h after envenomation, compared to the respective control (Fig. 3). However, the hyperglycemia was much more impressive in the NOD group, reaching glucose levels ≥ 200 mg/dL. During the analyzed time, glucose levels decrease, presenting a significant hypoglycemic period at 4 h for BALB/c and at 5 to 6 h for NOD animals. Nevertheless, the basal glucose levels for all challenged mice were reestablished after 12 h.

Fig. 3
Kinetic glucose level assay of BALB/c and NOD mice injected with Ts venom. Groups of mice were injected with 0.5 mg/kg of T. serrulatus venom (TsV) and glucose levels were measured throughout 24 h. Glucose was measured in mouse tail blood using a glucose meter (One Touch Ultra®, Lifescan, USA). *p< 0.05 and **p< 0.001 compared to the corresponding control group. Glucose levels were significant different at all points between control groups (BALB/c control vs NOD control). Data are presented as means ± SD (n= 4), which were analyzed by ANOVA and Tukey’s multiple comparison test

T. serrulatus venom affected the glycosylated hemoglobin (HbA1c) of NOD mice

The total glycosylated hemoglobin (HbA1c) was analyzed in mouse blood 30 days after envenoming. The results demonstrate that although Ts venom had induced hyperglycemia in BALB/c mice, it was not able to augment HbA1c (Fig. 4a). However, Ts venom caused a significant increase of HbA1c in envenomed NOD animals. Furthermore, the NOD group control also presented a significant increase of HbA1, indicating the diabetic condition of the mice.

Fig. 4
Blood glycosylated hemoglobin (HbA1c) percentage (%) and insulin plasma levels from BALB/c and NOD mice injected with Ts venom. Groups of mice were injected with 0.5 mg/kg of T. serrulatus venom (TsV). a HbA1c % was measured 30 days after challenge. b Insulin was measured 1 h after challenge. Results are expressed as means ± SD (n= 4), which were analyzed by ANOVA and Tukey’s multiple comparison test (*p< 0.05)

T. serrulatus venom increased insulin levels of NOD mice

The insulin levels were analyzed in mouse plasma during the peak of hyperglycemia (1 h after envenoming). The results demonstrate that Ts venom did not change insulin levels in BALB/c mice (Fig. 4b). As to the NOD group, a significant increase of insulin was observed in the envenomed mice. On the other hand, no significant changes on insulin levels were found in the NOD control group.

Discussion

The venom of T. serrulatus (Ts) is widely studied especially because of its biologically active compounds including the neurotoxins, a class of peptides mostly specific to voltage-gated sodium (Nav) or potassium (Kv) channels [²⁹]. So far, the actions of Ts neurotoxins on Nav and Kv channels have demonstrated a gamut of physiological responses, including the increasing of plasma glucose levels [¹⁴, ¹⁵, ³⁰, ³¹, ³², ³³, ³⁴, ³⁵,³⁶, ³⁷, ³⁸, ³⁹, ⁴⁰]. Although the mechanism of hyperglycemia induced by scorpions’ venom is not clearly understood, there are studies demonstrating that it can occur through the excessive release of catecholamine, increases in glucagon and cortisol, and alterations in thyroid hormone levels or insulin secretion [⁴¹, ⁴², ⁴³]. Furthermore, an isolated α-toxin from Ts, denominated Ts5, demonstrated a direct effect on isolated islets of Langerhans (not provided by catecholamine’s action), enhancing β-cell membrane depolarization and significantly potentiating glucose-induced insulin secretion [⁴³]. Therefore, this pioneering study aimed to elucidate the effect of hyperglycemia induced by Ts venom in diabetic individuals, using a NOD mouse model.

The Ts pooled venom used in the study showed a protein profile similar to others previous described, presenting protein masses corresponding to neurotoxins specific to sodium (NaTxs) and potassium (KTxs) channels [²⁷, ⁴⁴].

The in vivo assays demonstrated that blood glucose levels significantly increase 1 h after Ts injection (0.5 mg/kg), independently of the mouse model. Indeed, the highest glucose level at 1 h after envenoming has already been described in Wistar rats using the same dose (0.5 mg/kg) and intraperitoneal (i.p.) injection, and in BALB/c mice using 1 mg/kg of Ts venom and subcutaneous (s.c.) injection [¹⁴, ¹⁵]. A peculiar observation during our experimental design standardization was that either the highest dose of Ts venom (1 mg/kg) or the highest glucose basal levels (≥200 mg/dL) cause NOD mice lethality. Furthermore, the surviving mouse that presented basal glucose ≥ 200 mg/dL and received 0.5 mg/kg of Ts venom (n= 1) demonstrated a clinical sequela represented by an ocular disease with partial loss of vision, probably retinopathy (^{Additional file 1}).

The retina is an insulin-sensitive tissue and excess glucose or lipids may exert their noxious effects, accelerating retinal cell death [⁴⁵]. NOD mice frequently present diabetic retinopathy, with histological analysis showing loss of retinal microvessels and reduced perfusion of the retina, which result in hypoxia with evidence of disordered focal proliferation of new vessels [⁴⁶]. Definitely, diabetic retinopathy is a frequent cause of blindness developed by diabetic individuals after macular edema [⁴⁷]. Nevertheless, the retinopathy induced by Ts venom in diabetic mice requires further investigation.

During the Ts venom-induced glucose kinetic assay, we also observed a period in which the glucose reached levels lower than basal glycemia, which was previously described as a hypoglycemic period [¹⁴, ¹⁵]. BALB/c mice reduced glucose levels at 4 h following Ts venom injection, while NOD demonstrated a prolonged decrease of glucose levels at 5 to 6 h following Ts venom injection. It is known that beta cells of the islets of Langerhans sense changes in the plasma glucose levels and adjust the rate of insulin production aiming to maintain the homeostatic glucose plasma concentration [⁴⁸]. Thus, we assume that the production of insulin to control hyperglycemia induced by such envenoming remains high and, along with a decrease in glycogenolysis (due to hepatic glycogen depletion), causes a reduction of glucose levels.

Regarding NOD animals, the delayed hypoglycemia can be explained by the higher glucose levels required to be controlled, and the prolonged hypoglycemia (2 h) by the higher rates of insulin production. Indeed, a significant increasing of insulin was observed in NOD animals challenged with Ts venom. Although the increasing of this hormone in NOD mice seems peculiar, we assume that their diabetic disease was not sufficiently advanced to impair the insulin production significantly (the decrease of basal insulin of NOD control animals was not statistically significant compared to BALB/c control). In this sense, the animals still present a number of suitable insulin-producing beta cells in the islets of Langerhans.

According to the literature, the NOD model acquires insulin deficit after the age of 14 weeks (with high variety among individuals), that is, before this period, despite presenting high glucose levels, the animals still produce insulin. On the other hand, when these mice become overtly diabetic, they quickly lose weight and require insulin treatment [⁴⁹]. The effect of high insulin levels observed in NOD-envenomed mice is somewhat controversial. This effect may be beneficial, since insulin treatment in scorpion sting victims is known as a metabolic support, which controls the adverse metabolic response produced by catecholamines and other counter-regulatory hormones [⁵⁰]; or it could be unfavorable, since the injection of insulin after Ts envenoming can enhance the venom’s lethality [¹⁵]. Based on the latter, the lethality induced by Ts sting among diabetic individuals should be higher than that in healthy humans. In any case, insulin therapy after Ts envenoming should be further investigated in diabetic individuals, especially insulin-dependent ones.

On the other hand, BALB/c envenomed group did not present differences in insulin production compared to BALB/c control, although hyperinsulinemia has been reported previously during envenoming by the scorpion Mesobuthus tamulus concanesis and even by T. serrulatus [¹⁵, ⁴²]. However, in the Ts study, the authors used a rat model and i.p. injection, which may justify such differences.

We also evaluated the glycosylated hemoglobin (HbA1c) percentage, which is the primary method recommended before initiating therapy in diabetes patients [⁵¹]. Our results demonstrated that NOD control animals surely presented a diabetic clinical condition showing HbA1c higher than 7 % while the NOD envenomed group displayed a significant elevation, with levels higher than 8 %. The augmentation of HbA1c is considered a risk factor for diabetic neuropathy and retinopathy [⁵²]. This also explains why we observed only an ocular alteration in the envenomed group of NOD mice.

Currently, the treatment used for Ts accidents varies according to the clinical severity, which depends on the signs and symptoms manifested by the patient. Mild and moderate cases of Ts envenoming consist mostly of pain relief through analgesics at the sting site, orally or parenterally. On the other hand, severe scorpion envenoming cases require the mandatory use of the specific antivenom. In Brazil, the available antivenoms used for Ts envenoming are the scorpion antivenom (SAE or soro antiescorpiônico in Portuguese) and the arachnid antivenom (SAAr or soro antiaracnídeo in Portuguese). Their use is also compulsory in children under 7 years and in adults with previous health problems (e.g. hypertension and cardiovascular problems) even if they present mild or moderate clinical manifestations [¹, ⁵³]. In this regard, our results support the hypothesis that diabetic victims present a higher risk of developing severe envenoming. Therefore, we also advise consideration of the use of antivenom in cases of Ts envenoming in diabetic persons ─ a risk group for Ts envenoming severity.

Conclusion

Our study, for the first time, experimentally demonstrates that accidents caused by Ts scorpion in diabetic patients should be always considered a severe case of envenoming and that greater attention should be given to these cases. Moreover, as well as the envenomed NOD animals, these patients can present a higher risk of death and sequelae. We suggest that glucose, insulin and HbA1c levels need to be carefully monitored in diabetic patients.

Abbreviations

• DM  Diabetes mellitus
• HbA1c  Glycosylated hemoglobin
• i.p.  Intraperitoneal injection
• KTx  Neurotoxin specific potassium channels
• Kv  Voltage-gated potassium channel
• NaTx  Neurotoxin specific sodium channels
• Nav  Voltage-gated sodium channel
• NOD  Non-obese diabetic
• SDS  Sodium dodecyl sulfate
• Ts  Tityus serrulatus

Acknowledgements

Thanks to the Center for the Study of Venoms and Venomous Animals (CEVAP) of UNESP for enabling the publication of this paper (CAPES – grant n. 23038.006285/2011-21, AUXPE – Toxinologia – 1219/2011).

References

• ¹ Pucca MB, Oliveira FN, Schwartz EF, Arantes EC, Silva RML da. Scorpionism and dangerous species of Brazil. In: Gopalakrishnakone P, editor. Scorpion Venoms. Netherlands: Springer; 2015. p. 299–324.
• ² SUS, Portal da Saúde: Situação Epidemiológica - Dados. 2016. http://portalsaude.saude.gov.br Accessed 25 Jan 2016.
  » http://portalsaude.saude.gov.br
• ³ Reckziegel GC, Pinto VL. Scorpionism in Brazil in the years 2000 to 2012. J Venom Anim Toxins incl Trop Dis. 2014;20:20–46.
• ⁴ Chippaux JP. Epidemiology of envenomations by terrestrial venomous animals in Brazil based on case reporting: from obvious facts to contingencies. J Venom Anim Toxins incl Trop Dis. 2015;21:13.
• ⁵ Bucaretchi F, Fernandes LC, Fernandes CB, Branco MM, Prado CC, Vieira RJ, et al. Clinical consequences of Tityus bahiensis and Tityus serrulatus scorpion stings in the region of Campinas, southeastern Brazil. Toxicon. 2014;89:17–25.
• ⁶ Amitai Y. Clinical manifestations and management of scorpion envenomation. Public Health Rev. 1998;26(3):257–63.
• ⁷ Guidine PA, Cash D, Drumond LE, Souza ERGH de, Massensini AR, Willilams SC, et al. Brainstem structures are primarily affected in an experimental model of severe scorpion envenomation. Toxicol Sci. 2014;137(1):147–57.
• ⁸ Amaral CF, de Rezende NA, Freire-Maia L. Acute pulmonary edema after Tityus serrulatus scorpion sting in children. Am J Cardiol. 1993;71(2):242–5.
• ⁹ Bahloul M, Chaari A, Dammak H, Algia NB, Bouaziz M. Nosocomial scorpion envenomation: an unusual mode of scorpion sting. Clin Toxicol (Phila). 2010;48(9):962.
• ¹⁰ Nishioka SA, Silveria PV, Pereira CA. Scorpion sting on the penis. J Urol. 1993;150(5 Pt 1):1501.
• ¹¹ Nunan EA, Moraes MF, Cardoso VN, Moraes-Santos T. Effect of age on body distribution of Tityustoxin from Tityus serrulatus scorpion venom in rats. Life Sci. 2003;73(3):319–25.
• ¹² Fukuhara YD, Reis ML, Dellalibera-Joviliano R, Cunha FQ, Donadi EA. Increased plasma levels of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha in patients moderately or severely envenomed by Tityus serrulatus scorpion sting. Toxicon. 2003;41(1):49–55.
• ¹³ Cusinato DA, Souza AM, Vasconcelos F, Guimarães LF, Leite FP, Gregório ZM, et al. Assessment of biochemical and hematological parameters in rats injected with Tityus serrulatus scorpion venom. Toxicon. 2010;56(8):1477–86.
• ¹⁴ Pucca MB, Zoccal KF, Roncolato EC, Bertolini TB, Campos LB, Cologna CT, et al. Serrumab: a human monoclonal antibody that counters the biochemical and immunological effects of Tityus serrulatus venom. J Immunotoxicol. 2012;9(2):173–83.
• ¹⁵ Vasconcelos F, Sampaio SV, Garófalo MA, Guimarães LF, Giglio JR, Arantes EC. Insulin-like effects of Bauhinia forficataaqueous extract upon Tityus serrulatus scorpion envenoming. J Ethnopharmacol. 2004;95(2–3):385–92.
• ¹⁶ American Diabetes Association. Diagnosis and classification of Diabetes Mellitus. In Diabetes Care. 2004. p. S5,S6,S7,S8,S9,S10.
• ¹⁷ Greene JA. A classification of the different types of diabetes mellitus with a discussion of the diagnosis and treatment of each. Ariz Med. 1946;3:158–61.
• ¹⁸ World Health Organization (WHO). Global status report on noncommunicable diseases 2014. 2014 cited 2015; Available from: http://www.who.int/nmh/publications/ncd-status-report-2014/en/ Accessed 25 Jan 2016.
  » http://www.who.int/nmh/publications/ncd-status-report-2014/en/
• ¹⁹ Fukuda H. Report on a case of infantile diabetes. Showa Igakkai Zasshi. 1962;22:223-6. Article in Japanese.
• ²⁰ Pugliese A. Advances in the etiology and mechanisms of type 1 diabetes. Discov Med. 2014;18(98):141–50.
• ²¹ Kasuga M. Molecular basis for the development of type 2 diabetes mellitus. Nihon Rinsho. 2002;60 Suppl 7:468–76. Article in Japanese.
• ²² Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269–73.
• ²³ Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43(8):1066–84.
• ²⁴ Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980;29(1):1–13.
• ²⁵ Chhabra G, Dixit A. Structure modeling and antidiabetic activity of a seed protein of Momordica charantia in non-obese diabetic (NOD) mice. Bioinformation. 2013;9(15):766–70.
• ²⁶ Lowe RM, Farrell PM. A portable device for the electrical extraction of scorpion venom. Toxicon. 2011;57(2):244–7.
• ²⁷ Pucca MB, Amorim FG, Cerni FA, Bordon KC, Cardoso IA, Anjolette FA, et al. Influence of post-starvation extraction time and prey-specific diet in Tityus serrulatus scorpion venom composition and hyaluronidase activity. Toxicon. 2014;90:326–36.
• ²⁸ Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987;166(2):368–79.
• ²⁹ Ortiz E, Gurrola GB, Schwartz EF, Possani LD. Scorpion venom components as potential candidates for drug development. Toxicon. 2015;93:125–35.
• ³⁰ Pucca MB, Peigneur S, Cologna CT, Cerni FA, Zoccal KF, Bordon Kde C, et al. Electrophysiological characterization of the first Tityus serrulatus alpha-like toxin, Ts5: Evidence of a pro-inflammatory toxin on macrophages. Biochimie. 2015;115:8–16.
• ³¹ Peigneur S, Cologna CT, Cremonez CM, Mille BG, Pucca MB, Cuypers E, et al. A gamut of undiscovered electrophysiological effects produced by Tityus serrulatus toxin 1 on NaV-type isoforms. Neuropharmacology. 2015;95:269–77.
• ³² Cologna CT, Peigneur S, Rustiquel JK, Nonato MC, Tytgat J, Arantes EC. Investigation of the relationship between the structure and function of Ts2, a neurotoxin from Tityus serrulatus venom. FEBS J. 2012;279(8):1495–504.
• ³³ Cerni FA, Pucca MB, Peigneur S, Cremonez CM, Bordon KC, Tytgat J, et al. Electrophysiological characterization of Ts6 and Ts7, K⁺ channel toxins isolated through an improved Tityus serrulatus venom purification procedure. Toxins (Basel). 2014;6(3):892–913.
• ³⁴ Pucca MB, Cerni FA, Peigneur S, Bordon KC, Tytgat J, Arantes EC. Revealing the function and the structural model of Ts4: insights into the “non-toxic” toxin from Tityus serrulatus venom. Toxins (Basel). 2015;7(7):2534–50.
• ³⁵ Cologna CT, Peigneur S, Rosa JC, Selistre de Araujo HS, Varanda WA, Tytgat J, et al. Purification and characterization of Ts15, the first member of a new alpha-KTX subfamily from the venom of the Brazilian scorpion Tityus serrulatus Toxicon. 2011;58(1):54–61.
• ³⁶ Zoccal KF, Bitencourt CS, Secatto A, Sorgi CA, Bordon KC, Sampaio SV, et al. Tityus serrulatus venom and toxins Ts1, Ts2 and Ts6 induce macrophage activation and production of immune mediators. Toxicon. 2011;57(7–8):1101–8.
• ³⁷ Pessini AC, de Souza AM, Faccioli LH, Gregório ZM, Arantes EC. Time course of acute-phase response induced byTityus serrulatus venom and TsTX-I in mice. Int Immunopharmacol. 2003;3(5):765–74.
• ³⁸ Cupo P, Jurca M, Azevedo Marques MM, Oliveira JS, Hering SE. Severe scorpion envenomation in Brazil. Clinical, laboratory and anatomopathological aspects. Rev Inst Med Trop Sao Paulo. 1994;36(1):67–76.
• ³⁹ D’Suze G, Moncada S, González C, Sevcik C, Aguilar V, Alagón A. Relationship between plasmatic levels of various cytokines, tumour necrosis factor, enzymes, glucose and venom concentration following Tityus scorpion sting. Toxicon. 2003;41(3):367–75.
• ⁴⁰ Ribeiro EL, Pinto MC, Labarrere CR, Paes Leme FO, Chávez Olórtegui C, Melo MM. Biochemical profile of dogs experimentally envenomed with Tityus serrulatus scorpion venom. Toxicon. 2010;55(6):1125–31.
• ⁴¹ Murthy KR, Zare MA. Effect of Indian red scorpion (Mesobuthus tamulus concanesis, Pocock) venom on thyroxine and triiodothyronine in experimental acute myocarditis and its reversal by species specific antivenom. Indian J Exp Biol. 1998;36(1):16–21.
• ⁴² Murthy KRK, Haghnazari L. The blood levels of glucagon, cortisol and insulin following the injection of venom by the scorpion (Mesobuthus tamulus concanesis, Pocock) in dogs. J Venom Anim Toxins. 1999;5(1):47–55.
• ⁴³ Goncalves AA, Toyama MH, Carneiro EM, Marangoni S, Arantes EC, Giglio JR, et al. Participation of Na(+) channels in the potentiation by Tityus serrulatus alpha-toxin TsTx-V of glucose-induced electrical activity and insulin secretion in rodent islet beta-cells. Toxicon. 2003;41(8):1039–45.
• ⁴⁴ Pucca MB, Roncolato EC, Campos LB, Fernandes FS, Mendes GR, Bertolini TB, et al. Experimental Tityus serrulatusscorpion envenomation: age- and sex-related differences in symptoms and mortality in mice. J Venom Anim Toxins incl Trop Dis. 2011;17(3):325–32.
• ⁴⁵ Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401–11.
• ⁴⁶ Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B. Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. Exp Biol Med (Maywood). 2006;231(6):1101–5.
• ⁴⁷ Munoz de Escalona-Rojas JE, Quereda-Castaneda A, Garcia-Garcia O. Update of diabetic retinopathy for Primary Care physicians: Towards an improvement of telematic medicine. Semergen. 2016;42(3):172–6. Article in Spanish.
• ⁴⁸ Docherty K, Clark AR. Nutrient regulation of insulin gene expression. FASEB J. 1994;8(1):20–7.
• ⁴⁹ King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–94.
• ⁵⁰ Murthy KR, Hase NK. Scorpion envenoming and the role of insulin. Toxicon. 1994;32(9):1041–4.
• ⁵¹ American Diabetes Association (ADA): standards of medical care for patients with diabetes mellitus. Diabetes Care. 1999;22(Supple. 1):32–41.
• ⁵² McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004;27(6):1259–64.
• ⁵³ Pucca MB, Cerni FA, Pinheiro Junior EL, Bordon KC, Amorim FG, Cordeiro FA, et al. Tityus serrulatus venom - A lethal cocktail. Toxicon. 2015;108:272–84.

• Funding
  This study received financial support from the State of São Paulo Research Foundation (FAPESP –scholarships to MBP 2012/12954-6 and FAC 2012/13590-8), the National Council for Scientific and Technological Development (CNPq – scholarship to GHO) and NAP-TOXAN-USP (grant n. 12e125432.1.3).
• Ethics approval and consent to participate
  The present study was approved by the Ethics Commission for the Use of Animals (CEUA) at the USP Campus in Ribeirão Preto (protocol number 13.1.372.53.0). The use of Ts venom was approved by the Genetic Patrimony Management Board (CGEN/MMA), through the Access and Shipment Component of Genetic Heritage for scientific research purposes (number 010174/2014-1).

Additional files

Additional file 1: Representative comparison of eyeball of Ts envenomed and non-envenomed mice. Mice were injected with Ts venom (1 mg/kg). (A) Envenomed NOD mice with glucose basal level ≥ 200 mg/dL, retinopathy indication. (B) Envenomed BALB/c mice, typical ptosis. (C) BALB/c mice control (non-envenomed), normal eyeball. (PPTX 81 kb)

Publication Dates

• Publication in this collection
  2016

History

• Received
  29 Mar 2016
• Reviewed
  2 Sept 2016
• Accepted
  17 Sept 2016